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Abstract
Objective: The aim of this updated systematic review was to systematically assess 
the measurement properties of previously discussed and new quality‐of‐life patient‐
reported outcome measures (PROMs) in children and adults with eczema using the 
new COSMIN guideline.
Methods: A systematic literature search was conducted in PubMed and EMBASE. 
Eligible studies reported on measurement properties of quality‐of‐life PROMs for 
children and adults with eczema. The methodological quality of selected already 
known PROMs and new evidence identified through the literature search was as‐
sessed with the COSMIN Risk of Bias checklist. The adequacy of included PROMs 
was judged with updated quality criteria, and the quality of evidence of the summa‐
rized results was graded. Finally, PROMs were placed in a recommendation category 
(A‐C).
Results: In total, 133 measurement properties of nine different PROMs were as‐
sessed. No PROM could be placed in category A due to a lack of validation studies. 
Only the DLQI fulfilled the criteria for category C and therefore should not be recom‐
mended for use. All other PROMs were placed in category B, that is, they still have 
the opportunity to be recommended, but need further validation.
Conclusions: Currently, no PROM for quality of life can be recommended for use in 
children and adults with eczema. Further validation is needed. The DLQI cannot be 
recommended for future use.
K E Y W O R D S
atopic dermatitis, eczema, measurement properties, patient‐reported outcome measures, 
quality of life
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1  | BACKGROUND
Eczema (also called atopic dermatitis or atopic eczema) is a chronic 
inflammatory skin condition that affects up to 25% of children and 
2%‐3% of adults. Being one of the most common symptoms, pru‐
ritus is responsible for much of the skin disease burden.1 Eczema 
has profound impacts on the quality of life (QoL) of both affected 
children, their families, and adults.2 Quality of life is one of the 
four core outcome domains defined by the Harmonising Outcome 
Measures for Eczema (HOME) initiative (www.homef orecz ema.
org) and should be measured and reported in every clinical trial.3 
Quality of life is measured by self‐ or proxy‐reported question‐
naires, referred to patient‐reported outcome measures (PROMs). 
PROMs are used in clinical trials to reflect the patient's perspec‐
tive.4 In 2016, Heinl and colleagues published two systematic 
reviews, one for adults5 and one for children,6 in which measure‐
ment properties of quality‐of‐life instruments for eczema were 
assessed. To this end, the COnsensus‐based Standards for the se‐
lection of health Measurement INstruments (COSMIN) checklist7‐9 
was used, as well as content comparison, adequacy criteria, best 
evidence synthesis, and four degrees of recommendation (A‐D) 
based on the three criteria of the OMERACT (Outcome Measures 
in Rheumatology) filter (ie, truth, discrimination, and feasibility).10 
Since those systematic reviews of Heinl et al,5,6 the methodology 
of the assessment of measurement properties of patient‐reported 
outcome measures has been further developed. The new COSMIN 
Risk of Bias checklist was published in 2017 exclusively for use in 
systematic reviews. A new ordering of the measurement proper‐
ties and new labels for the rating system were established, and 
some standards on missing data, on the sample size, as well as the 
translation process, were removed.11 Criteria for good measure‐
ment properties were updated, a grading of the quality of evidence 
was established, and degrees of recommendation was formulated. 
Altogether, a whole guideline for systematic reviews of patient‐re‐
ported outcome measures was developed.12 For this reason, we 
looked at those previously discussed PROMs again using this new 
approach including the recently developed COSMIN Risk of Bias 
checklist, updated criteria for good measurement instruments, 
the GRADE approach, and a new categorization of the recom‐
mendation categories (A‐C) proposed by the COSMIN group.12 
Furthermore, the initial systematic reviews were updated by re‐
running the systematic literature search and applying the new ap‐
proach to the methodological assessment of the new evidence.
2  | MATERIAL S AND METHODS
2.1 | Literature search
A systematic, librarian‐assisted literature search in PubMed and 
EMBASE was performed on January 22, 2019. The initial search 
strategies (for children and adults) of Heinl and Apfelbacher13,14 
were merged, and the search string for PubMed is shown in detail 
in Appendix 1.
2.2 | Eligible studies
Eligible studies reported on dermatology‐ or disease‐specific QoL 
instruments for children or adults with eczema. We only included 
full‐text articles about the development and/or validation of meas‐
urement properties. In case of mixed patient samples, at least 50% 
of the patients had to be eczema patients or subgroup analyses for 
eczema patients were available.
2.3 | Study selection
Two independent reviewers judged titles and abstracts found in the 
literature search. Furthermore, the same reviewers applied the eligi‐
bility criteria to the relevant abstracts. In case of disagreement, con‐
sensus was reached by discussion within the research team.
2.4 | Data extraction
Data of previously discussed PROMs and data of the new evi‐
dence since 2015 were extracted by two independent reviewers. 
The selection of previously discussed instruments was based on 
decisions of the HOME initiative and aspects on feasibility (eg, 
PROMs which were not free of charge were excluded). Regarding 
the first systematic review by Heinl et al5 on adult QoL PROMs, 
only articles reporting on the DLQI (Dermatology Life Quality 
Index) and Skindex were used for data extraction. PROMs, such 
as DIELH (Deutsches Instrument zur Erfassung der Lebensqualität 
bei Hauterkrankungen [German instrument for the assessment of 
quality of life in skin diseases]),15,16 FLQA‐c (Freiburg Life Quality 
Assessment core module),17 FLQA‐d (Freiburg Life Quality 
Assessment for Dermatoses),18 and ISDL (Impact of Chronic 
Skin Disease on Daily Life),19 were not further considered for a 
potential recommendation since they were formerly placed in 
category C or D,5 and they were not considered as candidate 
instruments by the HOME initiative.20 Articles reporting on the 
QoLIAD (Quality of Life Index for Atopic Dermatitis)21 were not 
further assessed since this PROM is not available free of charge 
by the authors and, therefore, it cannot be recommended for 
use due to reasons of feasibility. For the same reason, the CIAD 
(Childhood Impact of Atopic Dermatitis)22 for children was not 
further assessed. Thus, regarding the second systematic review 
by Heinl et al (2016)13 on children with eczema, articles reporting 
Key Message
This updated systematic review gives an overview of all 
currently existing quality‐of‐life patient‐reported outcome 
measures for children and adults with atopic dermatitis. An 
assessment of the methodological quality of those instru‐
ments is used to formulate recommendations for future 
use.
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on the IDQoL (Infants' Dermatitis Quality of Life Index), CDLQI 
(Children's Dermatology Life Quality Index), CADIS (Childhood 
Atopic Dermatitis Impact Scale), and DISABKIDS were used for 
data extraction.
In a first step, the recently developed COSMIN Risk of Bias 
checklist was used to assess the methodological quality of the mea‐
surement properties of the single studies.11 The 10 boxes of the 
COSMIN Risk of Bias checklist are presented in Table 1. Content va‐
lidity is considered to be the most important measurement property 
since it should be clear that all items of a PROM are relevant, com‐
prehensive, and comprehensible regarding the construct of interest 
and the target population.23
In a second step, the quality of the measurement properties was 
assessed using updated criteria for good measurement properties 
(based on Terwee et al24) to see whether the respective measure‐
ment property of the PROM is sufficient (+), insufficient (−), or inde‐
terminate (?).25
In a third step, the quality of evidence was graded using the 
GRADE approach. If there were concerns about the trustworthiness 
of a result, the quality of evidence of the summarized results was 
downgraded per measurement property per PROM. Downgrading 
was possible for risk of bias, inconsistency, imprecision, and/or in‐
directness. The quality of evidence was judged as either high, mod‐
erate, low, or very low. If an overall rating was indeterminate or 
inconsistent, no grading of the quality of evidence was given.25
Finally, each PROM was placed in a recommendation category 
according to its adequacy and quality of evidence. The COSMIN 
group proposed three categories of recommendation.12 A PROM is 
placed in category A if there is sufficient content validity (any level) 
and at least low‐quality evidence for sufficient internal consistency. 
A PROM is placed in category C if there is high‐quality evidence for 
an insufficient measurement property. PROMs that can be neither 
categorized in A nor in C are placed in category B. PROMs in cate‐
gory A can be recommended for use, and results obtained with these 
PROMs can be seen as trustworthy. PROMs in category B need fur‐
ther validation; however, they still have the opportunity to be recom‐
mended for use. PROMs in category C should not be recommended 
for use. If only PROMs of category B are found, the PROM with the 
best evidence for content validity can be preliminarily recommended 
for use, until further evidence is given.25
3  | RESULTS
3.1 | Literature search
The systematic literature search identified 1944 records in PubMed 
and 1035 records in EMBASE. After deduplication, 2503 titles and 
abstracts were screened. Of 41 screened full texts, 10 papers ful‐
filled the eligibility criteria and were considered for data extraction 
(see Figure 1). Three papers reported on new PROMs (after 2015), 
and seven papers reported on previously discussed PROMs (before 
2015).
3.2 | Data extraction
In total, 34 papers (24 papers before 2015 and 10 papers after 
2015) reporting on nine PROMs were analyzed. The methodo‐
logical quality of 133 single studies was assessed (see Figure 2). 
Almost two thirds of all studies (60.9%) reported on the family 
of instruments DLQI, CDLQI, and IDQoL. Fifty (37.6%) measure‐
ment properties were rated as having very good methodological 
quality, twelve (9.0%) as having adequate, 48 (36.1%) as having 
doubtful, and 23 (17.3%) as having inadequate methodological 
quality.
Five of the nine PROMs were developed for children and four 
PROMs for adults. Relevant characteristics of the nine different 
PROMs, such as number of items, recall period, response categories, 
and target population, are presented in Table 2.
3.3 | Children—Summary of findings of previously 
discussed PROMs
3.3.1 | IDQoL—Infants Dermatitis Quality of Life27‐35
The IDQoL showed high‐quality evidence for sufficient reliability 
and construct validity and very‐low‐quality evidence for sufficient 
Box 1 PROM development
Content validityBox 2 Content validity
Box 3 Structural validity Internal structure
Box 4 Internal consistency
Box 5 Cross‐cultural validity\
Measurement invariance
Box 6 Reliability Remaining measurement properties
Box 7 Measurement error
Box 8 Criterion validity
Box 9 Hypotheses testing for construct 
validity
Box 10 Responsiveness
TA B L E  1   Boxes of the COSMIN Risk of 
Bias checklist
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content validity and responsiveness. The overall rating for internal 
consistency was indeterminate since no study on structural validity 
was available, and therefore, the criteria for “at least low evidence 
for sufficient structural validity” were not met (see Table 3).
3.3.2 | CDLQI—Children's Dermatology Life Quality 
Index31,32,34,36‐40
The quality of evidence for sufficient content validity and construct 
validity of the CDLQI was moderate. Internal consistency was inde‐
terminate for the same reason as for the IDQoL. No study reported 
intraclass correlation coefficients (ICCs) or a weighted kappa for 
reliability; thus, the overall rating was indeterminate (see Table 3).
3.3.3 | CADIS—Childhood Atopic Dermatitis Impact 
Scale41‐45
We found low to moderate quality of evidence for sufficient con‐
tent validity, reliability, and responsiveness of the CADIS. Studies 
on structural validity of the CADIS were available, but not all in‐
formation for a sufficient rating was reported. Thus, the overall 
rating for structural validity was indeterminate and, therefore, the 
overall rating for internal consistency as well. Regarding hypoth‐
eses testing for construct validity, the results did not show a clear 
pattern. Less than one third of our hypotheses could be confirmed. 
Since inconsistency could not be resolved, the overall rating was 
chosen to be inconsistent (see Table 3).
F I G U R E  1   Adapted Preferred 
Reporting Items for Systematic Reviews 
and Meta‐Analyses (PRISMA) Protocols 
2009 flow diagram.26 For more 
information, visit www.prisma‐state ment.
org
F I G U R E  2   Distribution of the quality 
of the single studies per PROM
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TA B L E  3   Summary of findings' table of the IDQoL, CDLQI, CADIS, and DISABKIDS
 Summary or pooled result Overall rating Quality of evidence
IDQoL
Content validity Relevance (+), comprehensiveness (+),  
comprehensibility (±)
Inconsistent → results based on the 
majority of results: sufficient
Very low (due to risk of 
bias and inconsistency)
Internal consistency Criteria for “at least low evidence for sufficient 
structural validity” not met
Indeterminate –
Reliability 0.89‐0.95 Sufficient High
Hypotheses testing for 
construct validity
18 out of 30 hypotheses confirmed Sufficient High (since most of the 
unconfirmed hypoth‐
eses came from inad‐
equate studies)
Responsiveness 1 out of 1 hypothesis confirmed, n = 25 Sufficient Very low (due to risk of 
bias and imprecision)
CDLQI
Content validity Relevance (+), comprehensiveness (+), compre‐
hensibility (+)
Sufficient Moderate (due to risk 
of bias)
Internal consistency Criteria for “at least low evidence for sufficient 
structural validity” not met
Indeterminate –
Reliability ICC or weighted kappa not reported Indeterminate –
Hypotheses testing for 
construct validity
11 out of 21 hypotheses confirmed Inconsistent → inconsistency 
resolved (based on the results of 
very good and adequate studies): 
sufficient
Moderate (due to 
inconsistency)
CADIS
Content validity Relevance (+), comprehensiveness (+), compre‐
hensibility (+)
Sufficient Low (due to risk of bias)
Structural validity Not all information for a sufficient rating 
reported
Indeterminate –
Internal consistency Criteria for “at least low evidence for sufficient 
structural validity” not met
Indeterminate –
Reliability 0.89‐0.96 Sufficient Moderate (due to risk 
of bias)
Hypotheses testing for 
construct validity
11 out of 38 hypotheses confirmed, 7 out of 
37 hypotheses partly confirmed
Inconsistent → inconsistency could 
not be resolved
–
Responsiveness 1 out of 1 hypothesis confirmed, n = 228 Sufficient Low (due to risk of bias)
DISABKIDS
Content validity Relevance (+), comprehensiveness (+), compre‐
hensibility (+)
Sufficient Moderate (due to risk 
of bias)
Internal consistency Criteria for “at least low evidence for sufficient 
structural validity” not met
Indeterminate –
Hypotheses testing for 
construct validity
1 out of 4 hypotheses confirmed, 1 out of 4 
hypotheses partly confirmed
Sufficient High (unconfirmed 
hypotheses came from 
inadequate studies)
InToDermQoL
Content validity Relevance (+), comprehensiveness (+), compre‐
hensibility (+)
Sufficient Moderate (due to risk 
of bias)
Internal consistency Criteria for “at least low evidence for sufficient 
structural validity” not met
Indeterminate –
Hypotheses testing for 
construct validity
1 out of 1 hypothesis confirmed Sufficient Moderate (due to risk 
of bias)
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3.3.4 | DISABKIDS—Atopic Dermatitis Module46,47
There was moderate quality of evidence for sufficient content va‐
lidity and high quality of evidence for sufficient construct validity 
of the DISABKIDS. Internal consistency was indeterminate due to a 
lack of studies on structural validity (see Table 3).
3.4 | Children—Summary of findings of new PROMs 
since 2015
3.4.1 | InToDermQoL—Infants and Toddlers 
Dermatology Quality of Life48
The InToDermQoL showed moderate quality of evidence for suf‐
ficient content validity and construct validity. Internal consistency 
was rated as indeterminate since no study on structural validity was 
performed (see Table 3).
3.5 | Adults—Summary of findings of previously 
discussed PROMs
3.5.1 | DLQI—Dermatology Life Quality 
Index18,37,49‐55
The DLQI was the only PROM with high‐quality evidence for an insuf‐
ficient measurement property, namely structural validity. This means 
there was at least one study of very good quality with a sample size 
larger than 100 patients available which reported this insufficient 
measurement property. Thus, internal consistency could not be de‐
termined. Even for cross‐cultural validity/measurement error, there 
was moderate quality of evidence for insufficiency, since differential 
item functioning was found. Content validity, reliability, and respon‐
siveness had a sufficient overall rating (with moderate to high quality 
of evidence). The results for hypotheses testing showed inconsistent 
results, and inconsistency could not be resolved (see Table 4).
3.5.2 | Skindex50,56,57
The Skindex was the only PROM with sufficient internal consistency 
since there is one paper available which performed a confirmatory fac‐
tor analysis on the Skindex and confirmed its structural validity.58 The 
quality of evidence was downgraded for one level (from high to moder‐
ate) due to imprecision because the total sample size was ≤100. For con‐
struct validity, inconsistent results could not be resolved (see Table 4).
3.6 | Adults—Summary of findings of new PROMs 
since 2015
3.6.1 | ABS‐A—Atopic Dermatitis Burden Scale 
for Adults59
The quality of evidence for sufficient content validity and reliability 
of the ABS‐A was low since there was only one study of doubtful 
quality available. There was high‐quality evidence for sufficient 
construct validity because most of the confirmed hypotheses came 
from studies of very good quality. The study on structural validity 
reported not all information for a sufficient rating. Thus, the overall 
rating of structural validity as well as the overall rating for internal 
consistency was indeterminate (see Table 4).
3.6.2 | ADerm‐IS—Atopic Dermatitis Impact Scale60
The development study of the ADerm‐IS was published in 2018, 
and until now, content validity is the only measurement property 
which has been assessed. This content validity study was the only 
content validity study with high quality of evidence for sufficient 
content validity since the study was of adequate quality (see 
Table 4).
3.7 | Degrees of recommendation
For all included PROMs, there was evidence for sufficient content 
validity in patients with eczema except for the Skindex. So far, no 
content validity study had been conducted in our target population. 
However, Skindex was the only PROM with at least low‐quality evi‐
dence for sufficient internal consistency because its structural va‐
lidity had been confirmed via confirmatory factor analysis.58 Since 
no PROM fulfilled the two criteria, evidence for sufficient content 
validity and at least low‐quality evidence for sufficient internal con‐
sistency, no candidate instrument could be placed in category A. 
The DLQI was the only instrument with high‐quality evidence for an 
insufficient measurement property and fulfilled therefore the crite‐
rion for category C (see Table 5).
All PROMs expect for the DLQI need further validation; how‐
ever, they still have the opportunity to be placed in category A and 
therefore recommended for use. The DLQI did not comply with the 
COSMIN guideline and cannot be recommended for future use due 
to insufficient measurement properties.
4  | DISCUSSION
This update of two systematic reviews assessed the measurement 
properties of nine different quality‐of‐life patient‐reported outcome 
measures for children and adults with eczema. None of the included 
PROMs could be placed in category A and therefore recommended 
for use due to a lack of validation studies of good quality. At least one 
study of very good quality reported insufficient structural validity 
of the DLQI according to the COSMIN guidelines.25 As a result, the 
DLQI was the only PROM for adults which cannot be recommended 
for future use.
In comparison with the former approach, the new COSMIN 
guideline for systematic reviews of patient‐reported outcome 
measures12 seems to be less strict and slightly more sympathetic 
toward candidate PROMs. In the initial systematic reviews, four 
degrees of recommendation (A‐D) were used in accordance with 
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the OMERACT filter since there was international consensus that 
the OMERACT quality criteria need to be met for eczema instru‐
ments as well.14 Almost all PROMs were categorized in category 
C or D except for the CADIS and the Spanish DLQI which reached 
category B. To be formerly placed in category A, a PROM had to 
meet all requirements of the OMERACT filter, such as truth (con‐
tent validity and construct validity), discrimination (reliability, 
internal consistency, and sensitivity to change), and feasibility (in‐
terpretability and ease of use). This meant a sufficient rating (+) 
for each measurement property which is almost impossible.14 With 
the new COSMIN degrees of recommendation, only sufficient con‐
tent validity and at least low‐quality evidence for sufficient internal 
consistency are required to be recommended as the most suitable 
PROM for the construct and population of interest. A PROM is now 
solely placed in category C if there is high‐quality evidence for an 
insufficient measurement property. Thus, more candidate PROMs 
have the potential to be recommended if further validation is 
given. With the new methodological approach, most of the studies 
(37.6%) were rated as “very good,” the best possible rating. In the 
previous systematic reviews, no measurement property of PROMs 
for children and only 1% of the measurement properties of PROMs 
for adults obtained the best possible COSMIN rating. Not only the 
degrees of recommendations are less strict, but also the COSMIN 
Risk of Bias checklist is more benevolent toward the single studies.
This study has several strengths and limitations: A strength of 
this updated systematic review is the fact that the initial search 
string was used to rerun the literature search. The two initial search 
strings for adults and children respectively were combined by our 
TA B L E  4   Summary of findings' table of the DLQI and Skindex (the red row indicates the criterion for a placement in category C and 
therefore no recommendation for use)
 Summary or pooled result Overall rating Quality of evidence
DLQI
Content validity Relevance (+), comprehensiveness (+), com‐
prehensibility (+)
Sufficient Moderate (due to risk of bias)
Structural validity Misfit/poor fit to the Rasch model, violation 
of unidimensionality (−)
Insufficient High
Internal consistency Criteria for “at least low evidence for suf‐
ficient structural validity” not met
Indeterminate –
Cross‐cultural validity/measure‐
ment error
DIF was found, n = 927 Insufficient Moderate (due to risk of bias)
Reliability 0.77 Sufficient Moderate (due to risk of bias)
Hypotheses testing for con‐
struct validity
10 out of 17 hypotheses confirmed Inconsistent → incon‐
sistency could not be 
resolved
–
Responsiveness 3 out of 3 hypotheses confirmed, n = 611 Sufficient High
Skindex
Internal consistency 0.84‐0.89; n = 63; at least low evidence for 
sufficient structural validitya
Sufficient Moderate (due to 
imprecision)
Hypotheses testing for con‐
struct validity
6 out of 11 hypotheses confirmed Inconsistent → incon‐
sistency could not be 
resolved
–
ABS‐A
Content validity Relevance (+), comprehensiveness (+), com‐
prehensibility (+)
Sufficient Low (due to risk of bias)
Structural validity Not all information for a sufficient rating 
reported
Indeterminate –
Internal consistency Criteria for “at least low evidence for suf‐
ficient structural validity” not met
Indeterminate –
Reliability 0.89 Sufficient Low (due to risk of bias)
Hypotheses testing for con‐
struct validity
3 out of 4 hypotheses confirmed Sufficient High (most of the confirmed 
hypotheses came from very 
good studies)
ADerm‐IS
Content validity Relevance (+), comprehensiveness (+), com‐
prehensibility (+)
Sufficient High
aSee He et al., 2014, table 9.58 
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academic librarian. Furthermore, at least two independent reviewers 
were involved in every single step of the assessment. One reviewer 
(MG) completed every step of the review process to ensure consis‐
tency. Discrepancies were discussed frequently and resolved within 
the research team. As in the initial systematic reviews, only two da‐
tabases, PubMed and EMBASE, were searched which can be listed 
here again as a limitation. Furthermore, reference lists of included 
studies were not hand‐searched and no other small databases were 
searched for relevant studies.
Despite the loosened requirements for a recommendation, no 
PROM could be placed in category A. Future validation research 
should focus on the PROMs of category B and fill in the validation gaps.
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APPENDIX 1
Search string Medline (via PubMed) 
#1: (modified precision search terms by Terwee et al 2009) 
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ity of results"[MeSH Terms] OR reproducib*[tiab] OR "psycho‐
metrics"[MeSH] OR psychometr*[tiab] OR clinimetr*[tiab] OR 
clinometr*[tiab] OR "observer variation"[MeSH] OR observer 
variation[tiab] OR "discriminant analysis" [MeSH] OR reliab*[tiab] 
OR valid*[tiab] OR coefficient[tiab] OR "internal consistency"[‐
tiab] OR (cronbach*[tiab] AND (alpha[tiab] OR alphas[tiab])) OR 
"item correlation"[tiab] OR "item correlations"[tiab] OR "item se‐
lection"[tiab] OR "item selections"[tiab] OR "item reduction"[tiab] 
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(test[tiab] AND retest[tiab]) OR (reliab*[tiab] AND (test[tiab] OR 
retest[tiab])) OR stability[tiab] OR interrater[tiab] OR inter‐rater[‐
tiab] OR intrarater[tiab] OR intra‐rater[tiab] OR intertester[tiab] 
OR inter‐tester[tiab] OR intratester[tiab] OR intra‐tester[tiab] OR 
interobserver[tiab] OR inter‐observer[tiab] OR intraobserver[tiab] 
OR intra‐observer[tiab] OR intertechnician[tiab] OR intertechni‐
cian[tiab] OR intratechnician[tiab] OR intra‐technician[tiab] OR in‐
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"factor analysis"[tiab] OR "factor analyses"[tiab] OR "factor struc‐
ture"[tiab] OR "factor structures"[tiab] OR dimensionality[tiab] OR 
subscale*[tiab] OR "multitrait scaling analysis"[tiab] OR "multitrait 
scaling analyses"[tiab] OR "item discriminant"[tiab] OR "interscale 
correlation"[tiab] OR "interscale correlations"[tiab]) OR ((error[tiab] 
OR errors[tiab]) AND (measure*[tiab] OR correlat*[tiab] OR evalu‐
at*[tiab] OR accuracy[tiab] OR accurate[tiab] OR precision[tiab] OR 
mean[tiab])) OR "individual variability"[tiab] OR "interval variabili‐
ty"[tiab] OR "rate variability"[tiab] OR "variability analysis"[tiab] OR 
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OR "standard error of measurement"[tiab] OR sensitiv*[tiab] OR 
responsive*[tiab] OR (limit[tiab] AND detection[tiab]) OR "minimal 
detectable concentration"[tiab] OR interpretab*[tiab] OR (small*[‐
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difference[tiab])) OR "meaningful change"[tiab] OR "minimal im‐
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bank"[tiab] OR "cross‐cultural equivalence"[tiab] OR accepta*[‐
tiab] OR "ease of use"[tiab] OR practica*[tiab] OR feasib*[tiab]) 
#2: Document types to be excluded and ani‐
mal‐only studies; erroneous NOT changed to OR 
("addresses"[Publication Type] OR "biography"[Publication Type] 
OR "case reports"[Publication Type] OR "comment"[Publication 
Type] OR "directory"[Publication Type] OR "editorial"[Publication 
Type] OR "festschrift"[Publication Type] OR "interview"[Publi‐
cation Type] OR "lectures"[Publication Type] OR "legal cases"[‐
Publication Type] OR "legislation"[Publication Type] OR "letter"[‐
Publication Type] OR "news"[Publication Type] OR "newspaper 
article"[Publication Type] OR "patient education handout"[Pub‐
lication Type] OR "popular works"[Publication Type] OR "con‐
gresses"[Publication Type] OR "consensus development confer‐
ence"[Publication Type] OR "consensus development conference, 
nih"[Publication Type] OR "practice guideline"[Publication Type]) 
OR ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])#3:#1 
NOT #2#4:(quality of life[MH] OR quality of life[TW] OR health 
status[MH] OR health status[TW] OR "activities of daily liv‐
ing"[MH] OR activities of daily living[TW] OR life quality* OR 
daily life[TW]OR health level[TW] OR level of health[TW] OR 
patient reported outcome[TW] OR CDLQI[TW] OR IDQOL[TW] 
OR Skindex[TW] OR Eczema Disability Index[TW])#5("dermatitis, 
atopic"[MeSH] OR atopic dermatitis[tiab] OR atopic eczema[‐
tiab] OR eczema[MeSH] OR eczema[tiab] OR "neurodermati‐
tis"[MeSH] OR Neurodermatitis[tiab] OR skin diseases[MH] OR 
skin disease*[tiab] OR dermatology[tiab])#6:#3 AND #4 AND 
#5#7: Only records from 2015 onwards#6 AND (2015:2010[mhda] 
OR 2015:2020[edat] OR 2015:2020[crdt] OR 2015:2020[dp] OR 
2015:2020[epdat] OR 2015:2020[ppdat])
